CBL0137 and NKG2A Blockade: A Novel Immuno-Oncology Combination Therapy for MYC-Overexpressing Triple-Negative Breast Cancers

Medicine, Oncology, Life Sciences, Immunology,
Triple-negative breast cancer   MYC overexpression   CBL0137   NKG2A blockade   Immunotherapy   Tumor microenvironment   Immune suppression  

Academic Background and Problem Statement Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, accounting for 15-20% of all breast cancer cases. Due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), TNBC is insensitive to hormone the...